NAD+‑Dependent Chromatin Licensing of AID Governs Age‑Related Decline in Class‑Switch Recombination

Kevin Wolf (MD/PhD)· Mar 23, 2026

Mechanism: Age-related NAD+ loss reduces SIRT1 activity, leading to repressed chromatin and hindered AID access, which lowers class-switch recombination (CSR). Readout: Readout: Restoring NAD+ increases SIRT1 activity, promotes open chromatin (high H3K9ac, low H3K9me3), boosts AID binding, and raises CSR rates and antibody diversity.

Hypothesis

Age‑associated NAD+ loss in B cells reduces SIRT1 activity, leading to hypoacetylated chromatin at immunoglobulin switch (S) regions and the Aicda locus. This chromatin state impedes AID access, thereby lowering class‑switch recombination (CSR) and contributing to the observed decline in antibody diversity.

Mechanistic Basis

SIRT1, an NAD+-dependent deacetylase, removes acetyl groups from histone H3K9ac and promotes a permissive euchromatin environment. When NAD+ falls, SIRT1 activity drops, allowing accumulation of repressive marks such as H3K9me3 at S regions and the Aicda promoter. Concurrently, PARP1 hyperactivation—driven by age‑related DNA damage—consumes NAD+ and deposits PAR chains that further compact chromatin. The combined effect creates a "closed" configuration that sterically hinders AID binding and its deaminase activity on switch DNA.

Predictions

In aged B cells, ChIP‑seq will show decreased H3K9ac and increased H3K9me3 at Sμ, Sγ1, and the Aicda promoter compared with young cells.
Restoring NAD+ (via NMN or CD38 inhibition) will increase SIRT1 activity, elevate H3K9ac, reduce H3K9me3, and rescue AID binding and CSR efficiency in vitro.
Genetic ablation of SIRT1 in young B cells will mimic the aged chromatin profile and suppress CSR, even when NAD+ levels are normal.

Experimental Design

Isolation: Purify naïve splenic B cells from young (3 mo) and aged (20 mo) mice.
Metabolic modulation: Treat aged cells with NMN (500 µM) or the CD38 inhibitor 78c (10 µM) for 24 h; include vehicle controls.
Readouts:
- Measure intracellular NAD+ (enzymatic assay).
- Quantify SIRT1 activity (fluorometric deacetylase assay).
- Perform ChIP‑qPCR for H3K9ac, H3K9me3, and AID at S regions and Aicda promoter.
- Assess CSR to IgG1 after LPS + IL‑4 stimulation (flow cytometry for surface IgG1).
- Include SIRT1 knockdown (siRNA) in young cells as a mechanistic control.
Expected outcome: NAD+ elevation should restore SIRT1 activity, increase H3K9ac, decrease H3K9me3, boost AID occupancy, and raise CSR rates to levels comparable with young cells.

Potential Caveats

Off‑target effects of NMN or CD38 inhibitors on other NAD+ consumers (e.g., PARPs, sirtuins) could confound interpretation; using SIRT1‑specific activators or CRISPR‑based SIRT1 rescue would strengthen causality.
Chromatin changes may be secondary to altered transcription factor networks (e.g., reduced E47); measuring E47 binding alongside histone marks will help dissect hierarchy.
In vivo validation (e.g., immunization with NP‑KLH and assessment of affinity‑matured IgG titers) is necessary to confirm that rescued CSR translates to functional humoral immunity.

Hypothesis

Mechanistic Basis

Predictions

In aged B cells, ChIP‑seq will show decreased H3K9ac and increased H3K9me3 at Sμ, Sγ1, and the Aicda promoter compared with young cells.

Restoring NAD+ (via NMN or CD38 inhibition) will increase SIRT1 activity, elevate H3K9ac, reduce H3K9me3, and rescue AID binding and CSR efficiency in vitro.

Genetic ablation of SIRT1 in young B cells will mimic the aged chromatin profile and suppress CSR, even when NAD+ levels are normal.

Experimental Design

Isolation: Purify naïve splenic B cells from young (3 mo) and aged (20 mo) mice.

Metabolic modulation: Treat aged cells with NMN (500 µM) or the CD38 inhibitor 78c (10 µM) for 24 h; include vehicle controls.

Readouts:

Measure intracellular NAD+ (enzymatic assay).
Quantify SIRT1 activity (fluorometric deacetylase assay).
Perform ChIP‑qPCR for H3K9ac, H3K9me3, and AID at S regions and Aicda promoter.
Assess CSR to IgG1 after LPS + IL‑4 stimulation (flow cytometry for surface IgG1).
Include SIRT1 knockdown (siRNA) in young cells as a mechanistic control.

Expected outcome: NAD+ elevation should restore SIRT1 activity, increase H3K9ac, decrease H3K9me3, boost AID occupancy, and raise CSR rates to levels comparable with young cells.

Potential Caveats

Off‑target effects of NMN or CD38 inhibitors on other NAD+ consumers (e.g., PARPs, sirtuins) could confound interpretation; using SIRT1‑specific activators or CRISPR‑based SIRT1 rescue would strengthen causality.

Chromatin changes may be secondary to altered transcription factor networks (e.g., reduced E47); measuring E47 binding alongside histone marks will help dissect hierarchy.

In vivo validation (e.g., immunization with NP‑KLH and assessment of affinity‑matured IgG titers) is necessary to confirm that rescued CSR translates to functional humoral immunity.